DelveInsight’s, “Acromegaly Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Acromegaly pipeline landscape. It covers the Acromegaly pipeline drug profiles, including Acromegaly clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Acromegaly emerging drugs, the Acromegaly pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Acromegaly pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Acromegaly Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Acromegaly clinical trials studies, Acromegaly NDA approvals (if any), and product development activities comprising the technology, Acromegaly collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Acromegaly Pipeline Report
- Over 15+ Acromegaly companies are evaluating 15+ Acromegaly pipeline therapies in various stages of development, and their anticipated acceptance in the Acromegaly market would significantly increase market revenue.
- The leading Acromegaly Companies includes Ionis Pharmaceuticals, Crinetics Pharmaceuticals, Camurus, Ono Pharmaceutical, Aquestive Therapeutics, Strongbridge Biopharma, Italfarmaco, Ipsen, Antisense Therapeutics, Dauntless Pharmaceuticals, TTY Biopharm, Peptron, DexTech Medical AB, Rani Therapeutics, OPKO Health, Inc., Amolyt Pharma, Foresee Pharmaceuticals, ADVANZ PHARMA, and others.
- Promising Acromegaly Pipeline Therapies includes octreotide FluidCrystal® injection depot, IONIS-GHR-LRx, SRL, Paltusotine, CAM2029 (octreotide subcutaneous depot), and others.
- The Acromegaly companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The Acromegaly pipeline therapies under development are focused on novel approaches to treat/improve Acromegaly.
Request a sample and discover the recent breakthroughs happening in the Acromegaly pipeline landscape @ Acromegaly Pipeline Outlook Report
Acromegaly Overview
Acromegaly is a disorder that occurs when your body makes too much growth hormone (GH). Produced mainly in the pituitary gland, GH controls the physical growth of the body. In adults, too much of this hormone causes bones, cartilage, body organs, and other tissues to increase in size. Common changes in appearance include enlarged or swollen nose, ears, hands, and feet. Acromegaly is most often diagnosed in middle-aged adults, but symptoms can appear at any age. In children, too much growth hormone causes a condition called gigantism NIH external link rather than acromegaly. Gigantism occurs when excess GH begins before the end of puberty, when children’s growth plates fuse or close. Having too much GH before the growth plates close causes children to grow tall in height.
Acromegaly Emerging Drugs Profile
- IONIS-GHR-LRX: Ionis Pharmaceuticals
IONIS-GHR-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of the growth hormone receptor (GHr) to decrease the circulating level of insulin-like growth factor-1 (IGF-1). IGF-1 is a hormone primarily produced in the liver that plays an important role in childhood growth and has anabolic effects in adults. Several different diseases result from abnormally low or high levels of IGF-1, or an inappropriate response to this hormone. When produced in excess, IGF-1 results in acromegaly, a chronic, slowly progressing and life-threatening disease. Currently, it is in Phase II stage of development to treat Acromegaly.
- Paltusotine: Crinetics Pharmaceuticals
Paltusotine (formerly CRN00808) is an orally available nonpeptide biased agonist that is designed to be highly selective for the somatostatin type 2 receptor. It was designed by the Crinetics discovery team to provide a once daily oral option for patients with acromegaly and neuroendocrine tumors that are currently treated by injected therapies that sell approximately $3.1 billion annually. Non-clinical chronic toxicology studies are complete and no dose limiting toxicity was identified at the maximum feasible doses in rats and dogs. Crinetics previously completed a Phase 1 trial that showed potent suppression of the growth hormone (GH) axis in healthy volunteers, which provided clinical proof-of-concept. In addition, the molecule’s observed plasma half-life of approximately 2 days suggested the potential for paltusotine for once daily oral administration. A subsequent Phase 1 trial showed that paltusotine was 70% orally bioavailable. Paltusotine is an investigational drug currently undergoing two Phase 2 clinical trials for the treatment of acromegaly, the ACROBAT Edge and Evolve trials. Paltusotine has been discovered, characterized, and developed by Crinetics and U.S. patents have been issued covering paltusotine to 2037. Currently, it is in Phase III stage of development to treat Acromegaly.
Find out more about the Acromegaly Diagnosis and Treatment of patients @ Acromegaly Ongoing Clinical Trials Analysis
Acromegaly Key Companies and Pipeline Therapies
- octreotide FluidCrystal® injection depot: Ionis Pharmaceuticals
- IONIS-GHR-LRx: Crinetics Pharmaceuticals
- SRL: Camurus
- Paltusotine: Ono Pharmaceutical
- CAM2029 (octreotide subcutaneous depot): Aquestive Therapeutics
Acromegaly Pipeline Therapeutics Assessment
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Discover more about the list of Acromegaly FDA-approved drugs for Acromegaly @ Acromegaly Treatment Landscape
Scope of the Acromegaly Pipeline Report
- Coverage- Global
- Acromegaly Companies- Ionis Pharmaceuticals (NYSE: IONS), Crinetics Pharmaceuticals (NYSE: CRNX), Camurus (NYSE: CAMX), Ono Pharmaceutical (NYSE: OPHLF), Aquestive Therapeutics (NYSE: AQST), Strongbridge Biopharma (NYSE: SBBP), Italfarmaco, Ipsen, Antisense Therapeutics (NYSE: ATHJF), Dauntless Pharmaceuticals, TTY Biopharm, Peptron, DexTech Medical AB (NYSE: DEX), Rani Therapeutics (NYSE: RANI), OPKO Health Inc (NYSE: OPK)., Amolyt Pharma, Foresee Pharmaceuticals, ADVANZ PHARMA, and others.
- Acromegaly Pipeline Therapies- octreotide FluidCrystal® injection depot, IONIS-GHR-LRx, SRL, Paltusotine, CAM2029 (octreotide subcutaneous depot), and others
- Acromegaly Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type
Dive deep into rich insights for Acromegaly Emerging Therapies and Ongoing Clinical Trials; visit @ Acromegaly Emerging Therapies and Key Players
Table of Content
- Introduction
- Executive Summary
- Acromegaly: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Paltusotine: Crinetics Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- IONIS-GHR-LRX: Ionis Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- RaniPill: Rani Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- AZP-3800: Amolyt Pharma
- Drug profiles in the detailed report…..
- Inactive Products
- Acromegaly Key Companies
- Acromegaly Key Products
- Acromegaly- Unmet Needs
- Acromegaly- Market Drivers and Barriers
- Acromegaly- Future Perspectives and Conclusion
- Acromegaly Analyst Views
- Acromegaly Key Companies
- Appendix
For further information on the Acromegaly Pipeline therapeutics, reach out to Acromegaly Market Drivers and Barriers
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
